Efficacy and safety of sorafenib plus hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma

Regmi, Parbatraj; Hu, Hai‐Jie; Lv, Tian-Run; Paudyal, Aliza; Sah, Ram Babu; Ma, Wen‐Jie; Jin, Yu; Li, Fuyu

doi:10.1016/j.suronc.2021.101663

Cited by 12 publications

(8 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…30 Regmi et al detected not significant difference in OS between sorafenib plus HAIC group and sorafenib group (HR, 0.70; 95% CI, 0.40-1.24; P > 0.05) by analyzing four RCTs. 31 Their subgroup analyses showed that patients with Child-Pugh score B (HR, 0.30; 95% CI 0.13-0.72; P < 0.05) and AFP < 400 ng/mL (HR, 0.72; 95% CI 0.52-0.99; P < 0.05) were associated with significantly improved OS in the sorafenib plus HAIC group. 31 Considering the limited number of included studies, the results should be interpreted with caution.…”

Section: Discussionmentioning

confidence: 98%

“…31 Their subgroup analyses showed that patients with Child-Pugh score B (HR, 0.30; 95% CI 0.13-0.72; P < 0.05) and AFP < 400 ng/mL (HR, 0.72; 95% CI 0.52-0.99; P < 0.05) were associated with significantly improved OS in the sorafenib plus HAIC group. 31 Considering the limited number of included studies, the results should be interpreted with caution. To our knowledge, our study is the largest meta-analysis comparing sorafenib plus HAIC with sorafenib alone for advanced HCC to date, and we provided more accurate and reliable evidence by conducting multiple subgroup analyses and sensitivity analysis.…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib alone for advanced hepatocellular carcinoma: A systematic review and meta‐analysis

Yin

Song

Guan

et al. 2023

J of Gastro and Hepatol

View full text Add to dashboard Cite

Background The combination of sorafenib and hepatic arterial infusion chemotherapy (HAIC) is expected to exert a synergistic anticancer effect. We conducted this systematic review to examine the efficacy and safety of sorafenib plus HAIC vs sorafenib alone for advanced hepatocellular carcinoma (HCC). Methods We systematically searched the PubMed, Embase, and Cochrane Library with the following search terms: “sorafenib,” “hepatic arterial infusion chemotherapy,” “HAIC,” “advanced,” “hepatocellular carcinoma,” and “HCC.” Pooled hazard ratios (HRs) and 95% CIs were calculated for overall survival (OS) and progression‐free survival (PFS), and we calculated the pooled risk ratios (RRs) and 95% CIs for objective response rate (ORR) and adverse events (AEs). Results We found that sorafenib plus HAIC was associated with significantly better OS (HR, 0.56; 95% CI, 0.37–0.83; P < 0.01), PFS (HR, 0.44; 95% CI, 0.27–0.72; P < 0.01), and ORR (RR, 3.77; 95% CI, 1.87–7.58; P < 0.01) than sorafenib alone in advanced HCC. Grade 3/4 AEs were more frequent in the sorafenib plus HAIC group, including leukopenia (RR, 4.54; 95% CI, 1.77–11.64; P < 0.01), neutropenia (RR, 7.81; 95% CI, 3.36–18.16; P < 0.01), thrombocytopenia (RR, 2.97; 95% CI, 1.98–4.46; P < 0.01), anemia (RR, 2.24; 95% CI, 1.22–4.09; P < 0.01), anorexia (RR, 2.37; 95% CI, 1.07–5.27; P = 0.03), nausea (RR, 2.98; 95% CI, 1.19–7.42; P = 0.02), and vomiting (RR, 3.99; 95% CI, 1.14–14.01; P = 0.03). Conclusion Sorafenib plus HAIC improved OS, PFS, and ORR compared with sorafenib alone in advanced HCC, with acceptable safety profile.

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 98%

Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib alone for advanced hepatocellular carcinoma: A systematic review and meta‐analysis

Yin

Song

Guan

et al. 2023

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

“…Therefore, HAIC combined with TKIs can generate favorable outcomes. Previous HAIC-related studies focused on HAIC combined with sorafenib as the rst-line treatment for Ad-HCC [20][21][22]. However, a randomized phase III study revealed that the e cacy of lenvatinib was comparable to that of sorafenib for the OS of untreated patients with Ad-HCC (23).…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of HAIC alone vs. HAIC combined with lenvatinib for treatment of advanced hepatocellular carcinoma

Long

Chen

et al. 2023

Med Oncol

View full text Add to dashboard Cite

To investigate e cacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib(HAIC-Len) and HAIC alone for the treatment of advanced hepatocellular carcinoma(Ad-HCC). MethodsTotally 349 patients with Ad-HCC participated in the research from February 2018 to October 2020. On the basis of propensity score matching(PSM), 132 and 110 cases were assigned to the HAIC group and the HAIC-Len group, respectively, with a ratio of 1:1. Progression-free survival(PFS), overall survival(OS), and complications were compared between two groups. The Kaplan-Meier method and log-rank test were utilized to estimate cumulative OS and PFS. Additionally, uni-and multi-variate Cox regression models were employed to identify signi cant independent factors. ResultsThe median follow-up period in this study was set to be 20.8 months. Following PSM, the one-, two-and three-year cumulative OS rates in the HAIC-Len and HAIC groups were 63.6%, 12.1%, and 3.0%, and 47.2%, 11.8%, and 2.7%, respectively, with a signi cant difference (P < 0.001). The rst-three-year cumulative incidence rates PFS in the HAIC-Len and the HAIC groups were 15.2%, 1.5%, and ND, and 11.8%, 4.5%, and 3.6%, respectively, with no signi cant difference detected(P = 0.092). BMI (HR: 0.709. 95% CI: 0.549, 0.915. P = 0.008) and AST(HR: 1.005. 95% CI: 1.003, 1.007. P < 0.001) represented independent prognostic factors for OS. Additionally, the two groups exhibited no signi cant difference in the incidence rates of adverse events. ConclusionsHAIC-Len signi cantly improved survival outcomes of patients with Ad-HCC and demonstrated acceptable toxicity compared to HAIC alone.

show abstract

“…Liver cancer is a common aggressive neoplasm with a high occurrence and high mortality, among which hepatocellular carcinoma (HCC) represents the most frequent form of liver cancer (Siegel et al 2020). Currently, surgical resection is the predominant therapeutic approach for human liver cancer, and sorafenib, a multi-kinase inhibitor, is the only first-line anti-cancer drug (Regmi et al 2021).…”

Section: Introductionmentioning

confidence: 99%

Rhamnazin Inhibits Hepatocellular Carcinoma Cell Aggressiveness in Vitro via Glutathione Peroxidase 4-Dependent Ferroptosis

Fei

Liu

Zheng

2022

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Ferroptosis, a newly recognized type of programmed cell death, is characterized by lipid peroxidation and implicated in multiple pathophysiological processes.Ferroptosis agonists are attracting tremendous attention for the clinical management of malignancy. We uncovered that rhamnazin exerted its anticancer property via reducing cell proliferation and invasion in hepatocellular carcinoma (HCC) cells. The ferroptosis inhibitor ferrostatin-1 (Fer-1) partially A c c e p t e d M a n u s c r i p t 2 reversed rhamnazin-triggered cell proliferation inhibition, indicating that ferroptosis contributed to the inhibitory potency of rhamnazin. Further characterization corroborated that exposure with rhamnazin, reactive oxygen species (ROS) accumulation and lipid peroxidation, and iron content were elevated in HCC cells. Mechanistically, we demonstrated that glutathione peroxidase 4 (GPX4) was involved in rhamnazin-initiated ferroptotic cell death. Overexpression of GPX4 weakened HCC cell ferroptosis caused by rhamnazin.Collectively, these results strongly suggest that rhamnazin exerts a ferroptoticinduce role in HCC cells by inhibiting GPX4 expression.

show abstract

Efficacy and safety of sorafenib plus hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma

Cited by 12 publications

References 26 publications

Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib alone for advanced hepatocellular carcinoma: A systematic review and meta‐analysis

Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib alone for advanced hepatocellular carcinoma: A systematic review and meta‐analysis

Efficacy and safety of HAIC alone vs. HAIC combined with lenvatinib for treatment of advanced hepatocellular carcinoma

Rhamnazin Inhibits Hepatocellular Carcinoma Cell Aggressiveness in Vitro via Glutathione Peroxidase 4-Dependent Ferroptosis

Contact Info

Product

Resources

About